Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])-Reference-Cited by-同舟云学术

Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])

Published:2021-06 Issue: Volume:148 Page:146-150
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Miller Alan B.,Januzzi James L.,O'Neill Blair J.^ORCID,Gundapaneni Balarama,Patterson Terrell A.,Sultan Marla B.,López-Sendón José

Funder

Pfizer Inc Boulder

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference16 articles.

1. A new staging system for cardiac transthyretin amyloidosis;Gillmore;Eur Heart J,2018

2. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types;Rapezzi;Circulation,2009

3. Natural history and therapy of TTR-cardiac amyloidosis: Emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs;Castaño;Heart Fail Rev,2015

4. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS);Ruberg;Am Heart J,2012

5. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review;Ruberg;J Am Coll Cardiol,2019

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients;Vascular Pharmacology;2024-09

2. Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence;The Egyptian Heart Journal;2024-07-10

3. Safety and efficacy of levosimendan in patients with cardiac amyloidosis;International Journal of Cardiology;2024-06

4. Incidencia y causas de hospitalización en pacientes con amiloidosis cardiaca por transtiretina (AC-ATTR) y por cadenas ligeras (AC-AL);Medicina Clínica;2024-04

5. Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis;Medicina Clínica (English Edition);2024-04